Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization
Pharmaceutics · 20.08.2025 · 17 (8) · 1074
DOI: 10.3390/pharmaceutics17081074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 20.08.2025. Verfasst von Shujun Fu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation, Chinese National Medical Product Administration, Beijing 100076, China. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Polyethylene glycol (PEG) has been widely utilized in optimizing therapeutics due to its excellent biocompatibility and chemical stability. However, multiple dosing of PEGylated drugs may result in toxicity due to PEG accumulation in tissues, leading to the formation of anti-PEG antibodies (APAs), which can accelerate drug clearance, reduce efficacy, and alongside enhanced side effects, such as allergic reactions. Notably, pre-existing APAs have also been detected in individuals with no prior exposure to PEGylated drugs, raising additional clinical concerns. This review summarizes the mechanisms of APA generation, the factors influencing PEG immunogenicity, and the biological consequences of APAs on drug pharmacokinetics, efficacy, and safety. We also discuss current challenges in APA detection and highlight strategies to minimize immunogenic responses, including PEG modification, immunomodulation, and alternative polymers. This review aims to provide a comprehensive reference for the rational design, evaluation, and clinical management of PEGylated drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Drug Evaluation, Chinese National Medical Product Administration, Beijing 100076, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zitieren
APA
Fu, S., Zhu, X., Huang, F., & Chen, X. (2025). Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization. Pharmaceutics, 17(8), 1074. https://doi.org/10.3390/pharmaceutics17081074
Vancouver
Fu S, Zhu X, Huang F, Chen X. Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization. Pharmaceutics. 2025;17(8):1074. doi:10.3390/pharmaceutics17081074
BibTeX
@article{Fu2025,
author = {Fu, Shujun and Zhu, Xueran and Huang, Fanghua and Chen, Xiaoyan},
title = {Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {8},
pages = {1074},
doi = {10.3390/pharmaceutics17081074}
}
EUVIMED